Evidence map›Paper›PMID 38438867›Full record

ArticleOrphanet journal of rare diseases2024

The health-care utilization and economic burden in patients with genetic skeletal disorders.

Luna Liu, Yingzhou Shi, Xiude Fan, Yangyang Yao, Wanhong Wu, Yang Tian, Huixiao Wu, Zongyue Li, Yanzhou Wang, Chao Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Orphanet journal of rare diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Luna LiuDepartment of Endocrinology, Shandong Provincial Hospital, Shandong University, 250021, Jinan, Shandong, China.
Yingzhou ShiDepartment of Endocrinology, Shandong Provincial Hospital, Shandong University, 250021, Jinan, Shandong, China.
Xiude FanDepartment of Endocrinology, Shandong Provincial Hospital, Shandong University, 250021, Jinan, Shandong, China.
Yangyang YaoDepartment of Pediatric Orthopedics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 250021, Jinan, Shandong, China.
Wanhong WuDepartment of Endocrinology, Shandong Provincial Hospital, Shandong University, 250021, Jinan, Shandong, China.
Yang TianDepartment of Endocrinology, Shandong Provincial Hospital, Shandong University, 250021, Jinan, Shandong, China.
Huixiao WuDepartment of Endocrinology, Shandong Provincial Hospital, Shandong University, 250021, Jinan, Shandong, China.
Zongyue LiDepartment of Endocrinology, Shandong Provincial Hospital, Shandong University, 250021, Jinan, Shandong, China.
Yanzhou WangDepartment of Pediatric Orthopedics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 250021, Jinan, Shandong, China.
Chao XuDepartment of Endocrinology, Shandong Provincial Hospital, Shandong University, 250021, Jinan, Shandong, China. doctorxuchao@163.com.ORCID 0000-0001-6743-8881
Shandong University · CNShandong Provincial Hospital · CN

Funding

National Natural Science Foundation of China 81974124
6 · The paper itself

Abstract

backgroundMost genetic skeletal disorders (GSD) were complex, disabling and life-threatening without effective diagnostic and treatment methods. However, its impacts on health system have not been well studied. The study aimed to systematically evaluate the health-care utilization and economic burden in GSD patients.

methodsThe patients were derived from 2018 Nationwide Inpatient Sample and Nationwide Readmissions Database. GSD patients were extracted based on International Classification of Diseases-10th revision codes.

resultsA total of 25,945 (0.12%) records regarding GSD were extracted from all 21,400,282 records in NIS database. GSD patients were likely to have significantly longer length of stay (6.50 ± 0.08 vs. 4.63 ± 0.002, P < 0.001), higher total charges ($85,180.97 ± 1,239.47 vs. $49,884.26 ± 20.99, P < 0.001), suffering more procedure, diagnosis and transferring records in comparison to patients with common conditions. GSD patients had a significantly higher 30-day all-cause readmission rate based on Nationwide Readmissions Database.

conclusionsThe heavy health-care utilization and economic burden emphasized the urgency for policy leaders, scientific and pharmaceutical researchers, health care providers and employers to identify innovative ways and take effective measurements immediately, and eventually to help improve the care, management, and treatment of these devastating diseases.

Indexed as

Financial StressPatient Acceptance of Health CareDatabases, FactualHealth PersonnelHumansInpatientsEconomic burdenGenetic skeletal disorderHealth-Care utilizationHealth systemRare bone disease

Identifiers

PMID38438867
PMCPMC10913423
OpenAlexW4392383324

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.